Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Boston Scientific Corporation Deutsche Bank Buy 22
Pfizer Inc. Morgan Stanley Buy 43
Abbott Laboratories Barclays Buy 52
Mylan N.V. Barclays Buy 57
PerkinElmer Inc. UBS Buy 60
Merck & Co. Inc. UBS Buy 68
DENTSPLY International Inc. Morgan Stanley Buy 70
St. Jude Medical Inc. Deutsche Bank Buy 77
AbbVie Inc. UBS Buy 78
Bristol-Myers Squibb Company Morgan Stanley Buy 80
Mallinckrodt Public Limited Company Barclays Buy 80
DaVita HealthCare Partners Inc. RBC Capital Mkts Buy 83
Endo International plc Deutsche Bank Buy 88
HCA Holdings, Inc. UBS Buy 90
Eli Lilly and Company BofA/Merrill Buy 90
Express Scripts Holding Company RBC Capital Mkts Buy 95
Johnson & Johnson Deutsche Bank Buy 105
CVS Health Corporation Deutsche Bank Buy 118
Stryker Corporation Argus Buy 120
Gilead Sciences Inc. Deutsche Bank Buy 124
1 2